Myelodysplastic Syndromes and Risk-Adapted Care
Research activity centers on myelodysplastic syndromes across low-risk, intermediate-risk, higher-risk, and very high-risk disease, including patients with transfusion-dependent anemia and those who are ineligible for allogeneic transplantation.
- Lower-risk MDS with anemia
- Higher-risk MDS and transplant-ineligible disease
- Myelodysplastic syndromes with transfusion dependence
- Post-transplant relapse in myeloid disease
Trials also address erythroid failure, hematologic improvement, and disease control in patients who have not responded to standard supportive or disease-directed treatment.
Genetically Defined Myeloid Neoplasms
The sponsor supports studies in IDH1-mutated and IDH2-mutated myelodysplastic syndrome, reflecting interest in molecularly targeted care for clonal myeloid disorders.
- IDH1-mutated MDS
- IDH2-mutated MDS
- Mutationally selected myeloid disease
These studies focus on treatment response and tolerance in molecularly characterized disease subsets.
Chronic Myelomonocytic Leukemia and Overlapping Myeloid Disorders
Clinical research includes higher-risk chronic myelomonocytic leukemia and related myeloid neoplasms, with attention to patients whose disease overlaps with myelodysplastic and acute leukemic features.
- Higher-risk CMML
- MDS/AML overlap
- Relapsed myeloid neoplasms after transplantation
Research in this area addresses disease control in advanced myeloid malignancy and post-transplant recurrence.
VEXAS Syndrome and Autoinflammatory Disease
The sponsor funds research in VEXAS syndrome, a severe autoinflammatory disorder linked to UBA1 mutation and refractory systemic symptoms.
- VEXAS syndrome
- UBA1-mutated disease
- Steroid-refractory inflammatory symptoms
These studies focus on symptom burden and inflammatory control in a rare adult-onset condition with hematologic involvement.
Erythropoiesis and Transfusion Independence
A major theme is treatment of anemia through strategies aimed at improving erythropoiesis and reducing red blood cell transfusion needs in lower-risk MDS.
- Erythropoiesis-stimulating agent failure
- Luspatercept-based approaches
- Transfusion independence
- Non-transfusion-dependent anemia
Research in this domain also includes optimization of supportive hematologic treatment for patients with persistent symptomatic anemia.
